Skip to main content
. 2021 Aug 5;12(8):772. doi: 10.1038/s41419-021-04042-7

Fig. 7. The inhibitory mechanism of APG-1252 and gemcitabine against nasopharyngeal carcinoma.

Fig. 7

APG-1252 plus gemcitabine synergistically suppressed NPC by activating caspase-dependent pathways, blocking the phosphor (p)JAK2/STAT3/MCL-1 signaling pathway, and inhibiting EMT process.